FILING ANALYSIS · THURSDAY, OCTOBER 15
RECURSION PHARMACEUTICALS, INC. RXRX — 8-K: Entry into a Material Definitive Agreement
negative
The company is raising approximately $200 million through a public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, which will lead to dilution for existing shareholders. The proceeds will be used to fund operating expenses and capital expenditures into 2029.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →